Renaissance in Organ Transplants and Convincing Europe Plans
International sales account for only 2.5% of the revenue mix
Quarter convinces with a revenue increase of 38% and a 163% higher net profit
Reading Time: 1 minute
TransMedics (TMDX, i) optimizes the procurement and transportation of donor organs with its Organ Care Systems (OCS). The CEO speaks of a global renaissance, "as the life-saving and cost-effective outcomes in the treatment of end-stage organ failure are increasingly recognized." In addition to hearts, livers, and lungs, the OCS Kidney System is being developed for up to 20,000 kidney transplants annually. Clinical trials for the third generation OCS systems are set to start later this year. The annual goal of 10,000 US transplants through the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
